NICE Issues Draft Guidance On Trastuzumab (Herceptin) For Early Breast Cancer

... NICE has today published draft guidance on Herceptin, just two weeks after the drug was licensed by the regulatory authorities for use in early breast cancer. The draft guidance recommends the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function. [click link for full article] ...